Novo Nordisk filed for approval of an oral, 25-mg formulation of its weight loss blockbuster “earlier this year,” according ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

1 Multiple trials, including hundreds of obese/overweight women in the menopausal/postmenopausal age group, reflect weight loss of at least 5% with three months of semaglutide treatment.

792 patients with type 2 diabetes and PAD with intermittent claudication were randomized to subcutaneous semaglutide 1 mg per week for 52 weeks or placebo. "While the trial recruited patients with ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Out of 1,363 screened candidates, 792 participants were selected and randomized 1:1 to subcutaneous semaglutide (1.0 mg once weekly) or placebo for 52 weeks. This cohort was 25% women and had a ...

Semaglutide medications like Ozempic and Wegovy have exploded in popularity in recent years due to their effectiveness in diabetes control and weight loss. Research has revealed additional ...

we shared preclinical data confirming that semaglutide delivered via the RaniPill® capsule exhibits similar bioavailability, pharmacokinetics, and weight loss as subcutaneous administration ...

Announced preclinical data demonstrating the bioequivalence of RT-114, a GLP-1/GLP-2 dual agonist (PG-102) delivered orally via the RaniPill® ...